The Valley Desk

NCT01979939 · Interventional trial

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Overall registry status Completed

Phase 3

Conditions Hepatitis C

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov